Targovax ASA logo

TRVX - Targovax ASA News Story

NOK6.42 -0.0  -0.5%

Last Trade - 2:43pm

Sector
Healthcare
Size
Micro Cap
Market Cap £41.8m
Enterprise Value £36.1m
Revenue £218k
Position in Universe 1007th / 1781

BRIEF-Targovax: To Fully Focus On ONCOS Oncolytic Virus Program

Thu 23rd May, 2019 7:38am
May 23 (Reuters) - Targovax ASA  TRVX.OL :
    * TARGOVAX TO FULLY FOCUS ON ONCOS ONCOLYTIC VIRUS PROGRAM
    * GOING FORWARD COMPANY WILL STRENGTHEN COMMITMENT TO ONCOLYTIC VIRUSES AND FOCUS RESOURCES
TO
ADVANCE ONCOS PROGRAM WITH FULL FORCE.
    * WILL STRENGTHEN COMMITMENT TO ONCOLYTIC VIRUSES AND FOCUS RESOURCES TO ADVANCE ONCOS
PROGRAM
WITH FULL FORCE.
    * ALTHOUGH TARGOVAX WILL NOT UTILIZE FUTURE RESOURCES ON TG PROGRAM IN ITS CURRENT FORM, WE
CONTINUE TO BELIEVE IN RAS AS AN IMPORTANT IMMUNOTHERAPEUTIC TARGET
    * WILL SEEK AND IMPLEMENT STRATEGIC ALTERNATIVES FOR TG
    * WE WILL SEEK ALTERNATIVE WAYS TO PROGRESS AND CAPTURE VALUE FROM TG - CEO

Source text for Eikon:  ID:nWkr7Tjr7V 
Further company coverage:  TRVX.OL 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.